ISDA

Entry Detail

PDB ID:

9CZT

Keywords:

TRANSFERASE

Title:

HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with compound 6

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2024-08-05

Release Date:

2024-12-18

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.69 Å

R-Value Free:

0.21

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase kinase kinase kinase 1
Mutations:T165E, S171E
Chain IDs:A, B
Chain Length:309
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q92918 Pfam ID:PF00069

Ligand Molecules

A1A1E

Primary Citation

Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer.

Gallego, R.A, Cho-Schultz, S, Del Bel, M, Dechert-Schmitt, A.M, Donaldson, J.S, He, M, Jalaie, M, Kania, R, Matthews, J, McTigue, M, Tuttle, J.B, Risley, H, Zhou, D, Zhou, R, Ahmad, O.K, Bernier, L, Berritt, S, Braganza, J, Chen, Z, Cianfrogna, J.A, Collins, M, Costa Jones, C, Cronin, C.N, Davis, C, Dress, K, Edwards, M, Farrell, W, France, S.P, Grable, N, Johnson, E, Johnson, T.W, Jones, R, Knauber, T, Lafontaine, J, Loach, R.P, Maestre, M, Miller, N, Moen, M, Monfette, S, Morse, P, Nager, A.R, Niosi, M, Richardson, P, Rohner, A.K, Sach, N.W, Timofeevski, S, Tucker, J.W, Vetelino, B, Zhang, L, Nair, S.K.Show

J.Med.Chem. 67 22002 22038 (2024)

PMID: 39651809 DOI: 10.1021/acs.jmedchem.4c01930

Abstact

Hematopoietic progenitor kinase 1 (HPK1/MAP4K1) represents a high interest target for the treatment of cancer through an immune-mediated mechanism. Herein we present highlights of the drug discovery campaign within the lactam/azalactam series of inhibitors that yielded a small molecule (21, PF-07265028), which was advanced to a phase 1 clinical trial (NCT05233436). Key components of the discovery effort included optimization of potency through mitigation of ligand strain as guided by the use of cocrystal structures, mitigation of ADME liabilities (plasma instability and fraction metabolism by CYP2D6), and optimization of kinase selectivity, particularly over immune-modulating kinases with high homology to HPK1. Structure-based drug design via leveraging cocrystal structures and lipophilic efficiency analysis proved to be valuable tools that ultimately enabled the delivery of a clinical-quality small molecule inhibitor of HPK1.

Legend

Protein

Chemical

Disease

Primary Citation of related structures